BWXT — BWX Technologies, Inc.
$189.31
Target: $238.00 (+25.7%)
P/E Ratio
50.5
P/E Forward
39.0
Dividend
0.58%
Market Cap
$17.2B
EPS
$3.75
Consensus
Buy
What they do
BWX Technologies, Inc. (NYSE: BWXT) manufactures ultra-high-precision nuclear components. It is, above all, a defense contractor: the sole supplier of the nuclear reactors that propel the U.S. Navy's submarines and aircraft carriers. HQ Lynchburg, Virginia.
Three businesses:
**
- Government Operations / Naval Nuclear — the heart. BWXT designs and builds the naval nuclear reactors for the U.S. Navy. It's a structural monopoly**: the Navy has no other qualified supplier, and the programs (Columbia- and Virginia-class submarines, aircraft carriers) run for decades. Hence the giant backlog (~$8.65 billion) and the revenue predictability.
**
- Advanced Technologies / micro-reactors — small, transportable nuclear reactors. It leads Project Pele**, the Department of Defense micro-reactor built to power remote bases, and participates in advanced-reactor projects for civilian and industrial use.
**
- BWXT Medical — produces radioisotopes** and radiopharmaceuticals used in imaging diagnostics and cancer treatments. It's a high-margin healthcare business with growing demand.
Capital allocation: pays a small dividend (~0.58%, ~$1.08/year) and reinvests in capacity. Leadership: CEO Rex D. Geveden. Q1 2026: revenue $860.2M, EPS $1.12, backlog $8.65 billion.
Why we like it
BWXT at $189.31 means buying the only manufacturer of the reactors that power the U.S. Navy — a monopoly backed by defense budgets — with two growth options thrown in for free (micro-reactors and nuclear medicine). Specific reasons:
- An irreplaceable monopoly: BWXT is the ONLY qualified supplier of U.S. naval reactors. The Navy can't switch suppliers — certifying another one would take decades and billions of dollars. That's a nearly unbreachable moat.
- Defense-shielded revenue: the ~$8.65 billion backlog and 20-30 year submarine/carrier programs provide cash-flow visibility almost no industry has. It doesn't depend on the economic cycle; it depends on the U.S. military budget (which is rising).
- The nuclear renaissance, low-risk version: instead of betting on a reactor startup, you buy the established supplier that already builds military-grade reactors and is expanding into micro-reactors (Project Pele) and civilian power.
- Nuclear medicine (optionality): BWXT Medical rides the theranostics boom — isotopes to detect and treat cancer — a high-margin, structurally growing market.
- AI's hunger for electricity: data centers' appetite for power is re-rating everything nuclear, and BWXT is a core supplier. Analysts: Buy, average target ~$238 (~+26%).
Key Risk
Risks:
- Dependence on the U.S. defense budget — the #1: most revenue comes from the Navy. A military spending cut, a delay in submarine/carrier programs, or a budget fight in Congress hits directly.
- High valuation: at ~50x earnings, the price already assumes growth; if execution disappoints, there's room for a correction.
- Single-customer concentration: when your main customer is one buyer (the U.S. government), you lose pricing power and depend on its agenda.
- Executing complex programs: building nuclear reactors is about as hard and regulated as it gets; cost overruns, delays or quality problems can eat the margin.
- A small dividend (~0.58%): the dividend income is symbolic; the thesis is growth, not income.
- New businesses without proven scale: micro-reactors and nuclear medicine are promising but still small next to the naval business; they'll take time to move the needle.
This is educational and informational content, not financial advice. Always consult a qualified financial advisor before making investment decisions.
Vectorial Data picked BWXT on 2026-06-08 at $189.31.
Full Research
BWX Technologies (BWXT) — Research Completo
Precio: $189.31 | P/E TTM: ~50.5x | Div Yield: ~0.58% | Market Cap: ~$17.2B USD
¿Qué es BWXT?
El único fabricante de los reactores nucleares que propulsan los submarinos y portaaviones de la Marina de EE.UU. Monopolio por diseño, respaldado por presupuestos de defensa. HQ Lynchburg, Virginia.
3 Negocios
| Segmento | Qué es | Nota |
|---|---|---|
| Naval Nuclear | Reactores para la U.S. Navy (submarinos, portaaviones) | Monopolio, backlog ~$8.65B |
| Advanced Tech / micro-reactores | Project Pele (DoD), reactores avanzados | Crecimiento |
| BWXT Medical | Radioisótopos para diagnóstico y cáncer | Alto margen |
Q1 2026
| Métrica | Q1 2026 |
|---|---|
| Ingresos | $860.2M |
| EPS | $1.12 |
| Backlog | $8.65 mil millones |
Capital Allocation
- Dividendo: ~$1.08/año (~0.58%).
- Reinversión en capacidad.
Liderazgo
- CEO: Rex D. Geveden.
Anchor Fact
Cada submarino y cada portaaviones nuclear de la Marina de Estados Unidos lleva dentro un reactor —y hay UNA sola empresa en el mundo autorizada para fabricarlos: BWXT—. La Marina no tiene un 'plan B': certificar a otro proveedor tomaría décadas. Eso le da a BWXT contratos militares que duran 20 o 30 años y un backlog de pedidos de ~$8,650 millones, sin importar si la economía sube o baja.
Top 5 Risks
- Dependencia del presupuesto de defensa de EE.UU.
- Valuación alta (~50x)
- Concentración en un cliente (el gobierno)
- Ejecución de programas nucleares complejos
- Dividendo simbólico (~0.58%) — tesis es crecimiento
Analyst Consensus
- Rating: Buy
- Target promedio: ~$238 (~+26% desde $189.31)
Tesis en una línea
El monopolio insustituible de los reactores de la Marina de EE.UU., blindado por presupuestos de defensa, con micro-reactores y medicina nuclear como opcionalidades de crecimiento.
Research fecha: 08 Jun 2026 | Próxima revisión: Dic 2026
Esto no es asesoría financiera.
This is not financial advice. Consult a certified financial advisor.
The author may hold positions in the securities discussed.
Past performance does not guarantee future results.